Phosphotyrosine-Based Phosphoproteomics of a Panel AML Cell Lines Reveals Oncogenic Signaling and Hyperactive Tyrosine Kinases as Targets for Treatment

Acute myeloid leukemia (AML) is a clonal disorder arising from hematopoietic progenitors developing in the myeloid pathway characterized by deregulated differentiation and maturation programs. In AML, tyrosine kinases have been implicated in leukemogenesis, and are associated with poor treatment outcome. Kinase inhibitor treatment has shown promise in improving patient outcome, however patients may benefit from better patient selection.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Carolien van Alphen, Jacqueline Cloos, Sander R. Piersma, Jaco C. Knol, Thang V. Pham, Johan van Meerloo, Gert J. Ossenkoppele, Henk M.W. Verheul, Jeroen J.W.M. Janssen, Connie R. Jimenez Source Type: research